



CBRN VACCINE PROGRAMS

Eric M. Espeland,
Ph.D. Chief, Vaccine
Branch

Smallpox Vaccine Program

- Overarching: Maintain preparedness levels, addressing the needs of at risk individuals with compromised immune system or with atopic dermatitis during a smallpox emergency

Near-term objectives

1. Stockpile maintenance of liquid frozen IMVAMUNE
2. Completion of activities for licensure of liquid frozen IMVAMUNE

Future objectives

1. Continue development of Freeze Dried IMVAMUNE to allow for potential transition to this product

Note: No additional vaccine development programs are planned for smallpox



Anthrax Vaccine Program

- Overarching: Expand BioThrax utility and pursue licensure of next generation vaccine(s) that provide equivalent protection with fewer doses at potentially lower cost

Near-term objectives – focus on enhancements of BioThrax®

1. Label expansion for PEP
2. Expansion of domestic manufacturing capacity
3. Adjuvanted formulation of BioThrax (Nuthrax)

Future objectives

1. Continue development and evaluation of rPA vaccine candidates
2. Adeno-vectored nasally delivered anthrax vaccine candidate



VHF Vaccine Program

Near-term objectives

1. BARDA is working with PHEMCE partners to maximize funding resources towards accelerating promising monovalent Ebola vaccine candidate products towards licensure
2. Establish an initial response capability for Ebola via stockpiling of monovalent vaccine candidate

Future objectives

1. Develop promising vaccine candidates against both Ebola and Marburg with emphasis on multivalent candidates
2. Objective to advance these products through end of Phase 2 development

Please see CBRN BAA Area of Interest #1 for information on minimum technical requirements for consideration

